Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
Bardet-Biedl Syndrome / Posted 11 months ago
The purpose of the study is to determine the effect of setmelanotide (RM-493) on weight, hunger assessments and other factors in patients with rare genetic disorders of obesity, including POMC deficiency, LepR deficiency, Bardet-Biedl syndrome and Alström syndrome.
- Study start date : 01/01/2017
- Study end date : 01/05/2021
- Wales-Based Study Contact : please speak to your clinician